Výsledky vyhledávání - "Giulio Francia"

Akademický článek

ErbB2/Her2-dependent downregulation of a cell death-promoting protein BLNK in breast cancer cells is required for 3D breast tumor growth

Autor: Xiaoyang Liu, Sandhya Chipurupalli, Peijia Jiang, Mahtab Tavasoli, Byong Hoon Yoo, Michael McPhee, Sina Mazinani, Giulio Francia, Robert S. Kerbel, Kirill V. Rosen

Publikováno v: Cell Death and Disease, Vol 13, Iss 8, Pp 1-10 (2022)

Abstract A significant proportion of breast cancers are driven by ErbB2/Her2 oncoprotein that they overexpress. These malignancies are typically treated with various ErbB2-targeted drugs, but many such cancers develop resistance to these agents and b

Externí odkaz: https://doaj.org/article/62c51b2c6a6e49339069aafeeb337811

Zobrazit plný text záznamu

Akademický článek

Precision therapeutic targeting of human cancer cell motility

Publikováno v: Nature Communications, Vol 9, Iss 1, Pp 1-14 (2018)

In this study, the authors identify and validate a halogen-substituted isoflavanone able to inhibit prostate cancer cell motility, invasion and metastasis in vitro and in vivo. They demonstrate its ability to selectively inhibit activation of client

Externí odkaz: https://doaj.org/article/bfb4cee65d69447bbe13390df2a07b87

Zobrazit plný text záznamu

Akademický článek

Spatiotemporal assessment of spontaneous metastasis formation using multimodal in vivo imaging in HER2+ and triple negative metastatic breast cancer xenograft models in mice.

Autor: Inga B Fricke, Raquel De Souza, Lais Costa Ayub, Giulio Francia, Robert Kerbel, David A Jaffray, Jinzi Zheng

Publikováno v: PLoS ONE, Vol 13, Iss 5, p e0196892 (2018)

Preclinical breast cancer models recapitulating the clinical course of metastatic disease are crucial for drug development. Highly metastatic cell lines forming spontaneous metastasis following orthotopic implantation were previously developed and ch

Externí odkaz: https://doaj.org/article/890f83c3666a49c6a3928d72dc7dcc3d

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Metronomic Ceramide Analogs Inhibit Angiogenesis in Pancreatic Cancer through Up-regulation of Caveolin-1 and Thrombospondin-1 and Down-regulation of Cyclin D1

Autor: Guido Bocci, Anna Fioravanti, Paola Orlandi, Teresa Di Desidero, Gianfranco Natale, Giovanni Fanelli, Paolo Viacava, Antonio Giuseppe^Naccarato, Giulio Francia, Romano Danesi

Publikováno v: Neoplasia: An International Journal for Oncology Research, Vol 14, Iss 9, Pp 833-845 (2012)

AIMS: To evaluate the antitumor and antiangiogenic activity of metronomic ceramide analogs and their relevant molecular mechanisms. METHODS: Human endothelial cells [human dermal microvascular endothelial cells and human umbilical vascular endothelia

Externí odkaz: https://doaj.org/article/424e515d3d2340ba94e2741890af427b

Zobrazit plný text záznamu

Akademický článek

Tumors That Acquire Resistance to Low-Dose Metronomic Cyclophosphamide Retain Sensitivity to Maximum Tolerated Dose Cyclophosphamide

Autor: Urban Emmenegger, Giulio Francia, Annabelle Chow, Yuval Shaked, Andrew Kouri, Shan Man, Robert S. Kerbel

Publikováno v: Neoplasia: An International Journal for Oncology Research, Vol 13, Iss 1, Pp 40-48 (2011)

Low-dose metronomic (LDM) chemotherapy is emerging as an alternative or supplemental dosing strategy to conventional maximum tolerated dose (MTD) chemotherapy. It is characterized primarily, but not exclusively, by antiangiogenic mechanisms of action

Externí odkaz: https://doaj.org/article/69848885684c4672bf9a79025fe2a446

Zobrazit plný text záznamu

Akademický článek

Development of a Resistance-like Phenotype to Sorafenib by Human Hepatocellular Carcinoma Cells Is Reversible and Can Be Delayed by Metronomic UFT Chemotherapy

Autor: Terence C. Tang, Shan Man, Ping Xu, Giulio Francia, Kae Hashimoto, Urban Emmenegger, Robert S. Kerbel

Publikováno v: Neoplasia: An International Journal for Oncology Research, Vol 12, Iss 11, Pp 928-940 (2010)

Acquired resistance to antiangiogenic drugs, such as sorafenib, is a major clinical problem. We studied development of a resistance to sorafenib in new preclinical models of human hepatocellular carcinoma (HCC) along with a strategy to delay such res

Externí odkaz: https://doaj.org/article/7d4360fe233b43e3a0454b3cd2ae3f7a

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání